Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. The company offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. It also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
Metrics to compare | ALDVI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALDVIPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.4x | 5.8x | −0.5x | |
PEG Ratio | −0.12 | 0.04 | 0.00 | |
Price/Book | −0.8x | 0.7x | 2.6x | |
Price / LTM Sales | 2.7x | 2.6x | 3.2x | |
Upside (Analyst Target) | 236.1% | 96.8% | 42.7% | |
Fair Value Upside | Unlock | 14.3% | 5.8% | Unlock |